[1]Patent:WO2009/40517,2009,A2.Locationinpatent:Page/Pagecolumn54-55
[2]HelveticaChimicaActa,2005,vol.88,p.1630-1657
[3]Patent:CN105732444,2016,A.Locationinpatent:Paragraph0057;0058;0059;0060
[4]OrganicProcessResearchandDevelopment,2016,vol.20,p.1482-1488
[5]Patent:WO2017/199264,2017,A1.Locationinpatent:Page/Pagecolumn24
[1]HelveticaChimicaActa,2005,vol.88,p.1630-1657
[1]HelveticaChimicaActa,2005,vol.88,p.1630-1657
[1]SyntheticCommunications,2010,vol.40,p.2520-2524
[2]JournalofMedicinalChemistry,2011,vol.54,p.4694-4720
[3]HelveticaChimicaActa,2005,vol.88,p.1630-1657
[4]Patent:WO2018/20406,2018,A1.Locationinpatent:Page/Pagecolumn14;15
[5]Patent:WO2018/29699,2018,A1.Locationinpatent:Page/Pagecolumn16
[1]HelveticaChimicaActa,2005,vol.88,p.1630-1657
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120920
Title: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Journal: Investigational new drugs 20120801
Title: HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Journal: Anticancer research 20120801
Title: Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120701
Title: A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Journal: Gynecologic oncology 20120501
Title: Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Journal: International journal of oncology 20120301
Title: Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.
Journal: Cancer research 20120215
Title: Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Journal: Annals of hematology 20120101
Title: Ovarian cancer: opportunity for targeted therapy.
Journal: Journal of oncology 20120101
Title: Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation.
Journal: Scientific reports 20120101
Title: Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.
Journal: Cancer management and research 20120101
Title: Novel therapies for aggressive B-cell lymphoma.
Journal: Advances in hematology 20120101
Title: Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.
Journal: OncoTargets and therapy 20120101
Title: Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Journal: BMC cancer 20120101
Title: Belinostat: clinical applications in solid tumors and lymphoma.
Journal: Expert opinion on investigational drugs 20111201
Title: Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Journal: Cell cycle (Georgetown, Tex.) 20110915
Title: Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.
Journal: The Journal of biological chemistry 20110902
Title: Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
Journal: Cancer chemotherapy and pharmacology 20110601
Title: Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520
Title: Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Journal: British journal of haematology 20110401
Title: Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Journal: Anticancer research 20110401
Title: Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Journal: British journal of cancer 20110301
Title: New drug therapies in peripheral T-cell lymphoma.
Journal: Expert review of anticancer therapy 20110301
Title: Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.
Journal: Journal of biomedicine & biotechnology 20110101
Title: Differential patterns of histone acetylation in inflammatory bowel diseases.
Journal: Journal of inflammation (London, England) 20110101
Title: Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Journal: PloS one 20110101
Title: Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.
Journal: Molecular medicine (Cambridge, Mass.) 20110101
Title: Epigenetic regulation of cancer-associated genes in ovarian cancer.
Journal: International journal of molecular sciences 20110101
Title: Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation.
Journal: PloS one 20110101
Title: Interpreting clinical assays for histone deacetylase inhibitors.
Journal: Cancer management and research 20110101
Title: Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.
Journal: Journal of biomedicine & biotechnology 20110101
Title: Chemotherapy in advanced bladder cancer: current status and future.
Journal: Journal of hematology & oncology 20110101
Title: Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
Journal: PloS one 20110101
Title: Chromatin remodeling, cell proliferation and cell death in valproic acid-treated HeLa cells.
Journal: PloS one 20110101
Title: Romidepsin in the treatment of cutaneous T-cell lymphoma.
Journal: Journal of blood medicine 20110101
Title: Epigenomics of ovarian cancer and its chemoprevention.
Journal: Frontiers in genetics 20110101
Title: The DAC system and associations with multiple myeloma.
Journal: Investigational new drugs 20101201
Title: Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Journal: Investigational new drugs 20101201
Title: The DAC system and associations with acute leukemias and myelodysplastic syndromes.
Journal: Investigational new drugs 20101201
Title: Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
Journal: Investigational new drugs 20101201
Title: Histone deacetylase inhibitors in the treatment of lymphoma.
Journal: Discovery medicine 20101101
Title: Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Journal: Oncotarget 20101101
Title: A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100915
Title: Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.
Journal: Electrophoresis 20100801
Title: Targeted treatment and new agents in peripheral T-cell lymphoma.
Journal: International journal of hematology 20100701
Title: A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
Journal: British journal of cancer 20100629
Title: Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Journal: European journal of cancer (Oxford, England : 1990) 20100601
Title: Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.
Journal: British journal of cancer 20100202
Title: Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100115
Title: Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Journal: Journal of oncology 20100101
Title: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
Journal: Journal of hematology & oncology 20100101
Title: Response to hydralazine-valproate in a patient with mycosis fungoides.
Journal: Case reports in medicine 20100101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20100101
Title: Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Journal: BMC cancer 20100101
Title: Epigenomics in cancer management.
Journal: Cancer management and research 20100101
Title: New treatments for myelodysplastic syndromes.
Journal: Mediterranean journal of hematology and infectious diseases 20100101
Title: Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
Journal: Anti-cancer drugs 20090901
Title: Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
Journal: British journal of cancer 20090804
Title: Epigenetic modifiers: basic understanding and clinical development.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090501
Title: Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Journal: Expert opinion on investigational drugs 20090401
Title: Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Journal: British journal of cancer 20090310
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090301
Title: Inhibition of HDAC6-dependent carcinogenesis: emerging, new therapeutic options besides belinostat.
Journal: International journal of cancer 20090115
Title: A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.
Journal: British journal of cancer 20090113
Title: Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090101
Title: Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
Journal: PloS one 20090101
Title: A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway.
Journal: PloS one 20090101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090101
Title: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Journal: Journal of hematology & oncology 20090101
Title: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Journal: International journal of oncology 20081001
Title: Histone deacetylase inhibitors as novel anticancer therapeutics.
Journal: Current oncology (Toronto, Ont.) 20081001
Title: Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
Journal: British journal of cancer 20080902
Title: A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Journal: European journal of haematology 20080901
Title: Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Journal: Histopathology 20080901
Title: Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Journal: Cancer chemotherapy and pharmacology 20080801
Title: Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.
Journal: Current medicinal chemistry 20080601
Title: Monitoring the effect of belinostat in solid tumors by H4 acetylation.
Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20080501
Title: Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
Journal: International journal of cancer 20080315
Title: A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080201
Title: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Journal: The Biochemical journal 20080115
Title: Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080115
Title: Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.
Journal: Cancer biomarkers : section A of Disease markers 20080101
Title: Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Journal: Molecular cancer 20080101
Title: HDAC inhibitors: clinical update and mechanism-based potential.
Journal: Biochemical pharmacology 20070901
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070501
Title: The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.
Journal: Journal of translational medicine 20070101
Title: Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histonedeacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2(8):721-8.
Title: Qian X, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5(8):2086-95.
Title: Chia S, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435.
